Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Lucy will add Wesana’s psilocybin and cannabidiol (CBD) combination investigational therapy, SANA-013 to its existing business of psychedelics manufacturing. SANA-013 is being developed for the treatment of several mental health/CNS-related conditions.
Lead Product(s): Psilocybine,Cannabidiol
Therapeutic Area: Psychiatry/Psychology Product Name: SANA-013
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Wesana Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 21, 2023